NEW YORK, Feb. 26 - Variagenics on Tuesday said that a significant drop in fourth-quarter total revenue conspired with increased R&D costs to send net loss spiraling skyward.

Revenue for the period ended Dec. 31 was $392,000, down from $1.2 million on year, and was attributable exclusively to research collaborations. Variagenics' sales in the current fourth quarter echoed last year's, as there were no sales of the company's NuCleave genotyping system.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.